Nature Medicine, Published online: 21 August 2026; doi:10.1038/s41591-026-04597-y
A feasibility trial delivering psilocybin-assisted therapy for treatment-resistant depression within the UK health service reports encouraging adherence and safety — it opens future questions about who is reached, where treatment happens and what standards will be needed to sustain it.
